Faculty Opinions recommendation of First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.

Author(s):  
Nico van Zandwijk
Sign in / Sign up

Export Citation Format

Share Document